KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShort-Term Debt repayments
Ratios

BeOne Medicines (ONC) Receivables - Net (2017 - 2025)

BeOne Medicines (ONC) has disclosed Receivables - Net for 9 consecutive years, with $21.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Receivables - Net fell 96.78% to $21.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $21.8 million, a 96.78% decrease, with the full-year FY2025 number at $21.8 million, down 96.78% from a year prior.
  • Receivables - Net was $21.8 million for Q4 2025 at BeOne Medicines, down from $39.1 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $770.8 million in Q2 2025 to a low of $11.3 million in Q3 2022.
  • A 5-year average of $159.5 million and a median of $48.9 million in 2024 define the central range for Receivables - Net.
  • Peak YoY movement for Receivables - Net: skyrocketed 2642.01% in 2023, then tumbled 96.78% in 2025.
  • BeOne Medicines' Receivables - Net stood at $12.0 million in 2021, then surged by 89.65% to $22.8 million in 2022, then skyrocketed by 1471.88% to $358.0 million in 2023, then soared by 88.89% to $676.3 million in 2024, then crashed by 96.78% to $21.8 million in 2025.
  • Per Business Quant, the three most recent readings for ONC's Receivables - Net are $21.8 million (Q4 2025), $39.1 million (Q3 2025), and $770.8 million (Q2 2025).